News

The Pulmonary Hypertension Association (PHA) is organizing a series of events, called “PHA on the Road: PH Patients and Families Education Forum,” to give the pulmonary hypertension (PH) community a free, day-long platform through which to network with other patients, medical professionals, and PH experts. Two upcoming…

The Pulmonary Hypertension Association (PHA) is urging the U.S. Senate to support the Pulmonary Hypertension Research and Diagnosis Act of 2016 (S. 3361), introduced this week by the Sen. Bob Casey and aiming to speed the development of new treatments and improve the care of people with pulmonary…

The use of nitrite salts for the treatment of cardiovascular conditions, such as pulmonary hypertension, is now patented by the U.S. Patent and Trademark Office (USPTO). The new patent (US 20060182815 A1) was awarded to Gordon G. Power with Loma Linda University, and a team of investigators from several other universities,…

Breathing exercises aimed at improving the respiratory system’s muscular strength and endurance can considerably benefit pulmonary hypertension (PH) patients and improve their overall life quality. Researchers in Greece in the article, “Benefits of inspiratory muscle training in patients with pulmonary hypertension: A pilot study,” published in the Hellenic Journal of Cardiology, reported…

Research into, and care of, patients with both congenital heart disease and pulmonary arterial hypertension (PAH) need to be optimized so that advances in PAH management and care can also benefit these patients, two PAH experts argue. George Giannakoulas, MD, PhD, at the Aristotle University of Thessaloniki in Greece, and…

Sounds produced in the heart, reworked using a classification algorithm based on an automated speech recognition, were analyzed and seen to lead to more accurate diagnoses of pulmonary hypertension (PH) in patients than those done by physicians listening to the same heart recordings, according to the study,  “Acoustic diagnosis of pulmonary hypertension: automated…

A molecule called PHD2 in the cells lining blood vessels in the lungs protects mice from the blood vessel remodeling leading to pulmonary arterial hypertension (PAH), as removal of the factor triggered numerous changes linked to the condition. The findings suggest that PHD2 is a factor that is downstream of…

A study published in the journal Nature Communications reported the case of several patients with pulmonary arterial hypertension (PAH) who carried more than one pathogenic mutation in several genes. The researchers found that these patients had more severe symptoms, which suggests that additional mutations can worsen the pathology of the…

Rats with induced pulmonary hypertension (PH) and all its symptoms that were then treated with a modified strain of Lactobacillus, a probiotic bacteria engineered to produce a specific oral peptide, showed a reversal in those symptoms: reduced blood pressure, reduced heart wall thickness, and improved heart contractility. The results were recently…

At the upcoming Evening of Hope Gala, the California chapter of the Pulmonary Hypertension Association (PHA) will recognize two pioneers in the field of pulmonary hypertension (PH): Jean-Paul Clozel, MD, a cardiologist who is the chief executive officer the of the biopharmaceutical company Actelion, and his wife Martine Clozel, MD, a pediatrician who…

Liraglutide, a drug used to treat type 2 diabetes (brand name, Victoza) and obesity (brand name, Saxenda), is currently being evaluated as a possible therapy for Parkinson’s disease. Now, a new study suggests that liraglutide may also be quite effective in treating pulmonary arterial hypertension (PAH). The study, “Liraglutide prevents and reverses monocrotaline-induced…

Unfortunately, there is still no known cure available for pulmonary hypertension, but research has been evolving and doctors and scientists have been discovering some new ways to approach the lung condition. You might be interested in reading more about Uptravi (selexipag) as a treatment for PH. According to…